We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
-20.92%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$220M
AUM Growth
-$80.2M
Cap. Flow
-$4.32M
Cap. Flow %
-1.97%
Top 10 Hldgs %
80.97%
Holding
32
New
7
Increased
6
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$19.7M
2
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$8.86M
3
ASMB icon
Assembly Biosciences
ASMB
+$4.59M
4
CASC
Cascadian Therapeutics, Inc.
CASC
+$3.22M
5
OREX
Orexigen Therapeutics, Inc.
OREX
+$3.21M

Top Sells

Rank Stock Value
1
ATRA icon
Atara Biotherapeutics
ATRA
+$12.7M
2
EPZM
Epizyme, Inc
EPZM
+$3.9M
3
ARRY
Array Biopharma Inc
ARRY
+$2.88M
4
BITI
BIOTIE THERAPIES CORP SPONSORED ADR
BITI
+$2M
5
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$1.71M

Sector Composition

Rank Sector Weight
1 Healthcare 88.28%
2 Miscellaneous 11.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KYNB
1
Kyntra Bio
KYNB
$32.5M
$27M 12.28%
49,216
+1,000
+2% +$606K
ATRA icon
2
Atara Biotherapeutics
ATRA
$92.3M
$25.3M 11.5%
32,138
-10,390
-24% -$12.7M
TVTX icon
3
Travere Therapeutics
TVTX
$6.19B
$20.4M 9.29%
1,007,660
+666,010
+195% +$19.7M
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$19.2M 8.74%
1,492,700
-193,100
-11% -$3.9M
ASMB icon
5
Assembly Biosciences
ASMB
$694M
$18M 8.21%
157,256
+26,080
+20% +$4.59M
KITE
6
DELISTED
Kite Pharma, Inc.
KITE
$15.7M 7.13%
281,400
– –
DCOY
7
Decoy Therapeutics
DCOY
$1.9M
$11.2M 5.1%
1
– –
COLL icon
8
Collegium Pharmaceutical
COLL
$786M
$10.3M 4.68%
465,118
– –
ATYR
9
aTyr Pharma
ATYR
$53M
$8.62M 3.92%
60,033
+257
+0.4% +$58.6K
NBRV
10
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$7.94M 3.61%
+3,342
New +$8.86M
KIN
11
DELISTED
Kindred Biosciences, Inc.
KIN
$6.88M 3.13%
1,323,431
+29,000
+2% +$179K
GNVC
12
DELISTED
GenVec, Inc.
GNVC
$4.59M 2.09%
198,641
– –
EIGR
13
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.98M 1.36%
6,318
– –
CASC
14
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.58M 1.18%
+157,250
New +$3.22M
AKTX
15
Akari Therapeutics
AKTX
$20.8M
$2.42M 1.1%
+126
New +$1.49M
FWP
16
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$2.4M 1.09%
14,571
-8,141
-36% -$1.71M
FPRX
17
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.29M 1.04%
+149,000
New +$3.2M
CALA
18
DELISTED
Calithera Biosciences, Inc
CALA
$2.26M 1.03%
20,774
– –
GILD icon
19
CALL
Gilead Sciences
GILD
$181B
$2.15M 0.98%
+3,255
New +$362K
OREX
20
DELISTED
Orexigen Therapeutics, Inc.
OREX
$1.98M 0.9%
+93,796
New +$3.21M
QLTI
21
DELISTED
QLT Inc
QLTI
$1.7M 0.77%
638,900
+238,900
+60% +$877K
BHC icon
22
CALL
Bausch Health
BHC
$2.36B
$1.35M 0.61%
+1,265
New +$295K
GYRE icon
23
Gyre Therapeutics
GYRE
$699M
$261K 0.12%
498
-289
-37% -$441K
RGLS
24
CALL
DELISTED
Regulus Therapeutics
RGLS
$35K 0.02%
11
– –
MCRB icon
25
Seres Therapeutics
MCRB
$51.3M
– –
-2,000
Closed -$1.66M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q3 2015 Portfolio in Review

As of Q3 2015, EcoR1 Capital held 32 positions worth $220M, down 27% from $300M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

EcoR1 Capital's Q3 2015 filing shows 7 new, 6 increased, 4 reduced and 7 closed positions. Its largest new stake was Nabriva Therapeutics plc Ordinary Shares Ireland: 3,342 shares worth $7.94M. The largest sale was Atara Biotherapeutics, an estimated $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 86% a quarter earlier, followed by Miscellaneous.

  • EcoR1 Capital's largest Q3 2015 buy was Nabriva Therapeutics plc Ordinary Shares Ireland: 3,342 shares worth $7.94M.
  • EcoR1 Capital added most to Travere Therapeutics in Q3 2015, an estimated $19.7M increase.
  • EcoR1 Capital's biggest Q3 2015 reduction was Atara Biotherapeutics, cutting an estimated $12.7M.
  • EcoR1 Capital fully exited Array Biopharma Inc in Q3 2015, selling an estimated $2.88M.
  • EcoR1 Capital's ten largest holdings make up 81% of its $220M portfolio in Q3 2015.
  • EcoR1 Capital opened 7 new positions and closed 7 in Q3 2015.
  • EcoR1 Capital's portfolio value fell 27% quarter-over-quarter to $220M.

Based on EcoR1 Capital's 13F filing for Q3 2015, filed 16 Nov 2015.